Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.43 |
| ▸ | TSHR | P16473 | 4/20 | 0.43 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | PKM | P14618 | 3/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.39 |
| ▸ | CASP1 | P29466 | 3/20 | 0.39 |
| ▸ | RECQL | P46063 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | PTPN7 | P35236 | 2/20 | 0.39 |
| ▸ | BLM | P54132 | 2/20 | 0.39 |
| ▸ | CASP7 | P55210 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23057948 | 0.82 | LMNA (0.39) | ALDH1A1TDP1TSHRPIK3R1PIK3CA | |
| SCHEMBL16401835 | 0.80 | PIK3R1 (0.56) | ALDH1A1TSHRPIK3R1PIK3CAPOLB | |
| SCHEMBL26259920 | 0.77 | ALDH1A1 (0.41) | ALDH1A1TDP1TSHRPIK3R1PIK3CA | |
| SCHEMBL26259526 | 0.75 | CFTR (0.36) | ALDH1A1TDP1TSHRPOLBKDM4E | |
| SCHEMBL1194484 | 0.75 | ALDH1A1 (0.55) | ALDH1A1TDP1TSHRKDM4EMAPT | |
| SCHEMBL26259656 | 0.74 | MET (0.34) | ALDH1A1TDP1POLBKDM4EMAPT | |
| SCHEMBL16411262 | 0.73 | CFTR (0.37) | ALDH1A1TDP1TSHRPOLBKDM4E | |
| SCHEMBL545684 | 0.73 | ALDH1A1 (0.52) | ALDH1A1TDP1TSHRKDM4EMAPT | |
| Phosphine SCHEMBL2238711 | 0.73 | ALDH1A1 (0.52) | ALDH1A1TDP1TSHRKDM4EMAPT | |
| SCHEMBL13091138 | 0.72 | NPC1 (0.43) | ALDH1A1TDP1TSHRPOLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11701370-B2 | Phosphonium ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701370-B2 | Phosphonium ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11643404-B2 | Ester substituted ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643404-B2 | Ester substituted ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11377422-B2 | Charged ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2022-07-05 | — | — | US | disclosed |
| US-20210128589-A1 | PHOSPHONIUM ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. | 2021-05-06 | — | — | US | disclosed |
| US-20210128578-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | NOCION THERAPEUTICS INC (US) | 2021-05-06 | — | — | US | disclosed |
| US-20210130380-A1 | PHOSPHONIUM ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. | 2021-05-06 | — | — | US | disclosed |
| US-10968179-B2 | Charged ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20210070734-A1 | ESTER SUBSTITUTED ION CHANNEL BLOCKERS AND METHODS FOR USE | NOCION THERAPEUTICS INC (US) | 2021-03-11 | — | — | US | disclosed |
| US-10927096-B2 | Ester substituted ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2021-02-23 | — | — | US | disclosed |
| US-10842798-B1 | Charged ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200290953-A1 | Charged Ion Channel Blockers and Methods for Use | Nocion Therapeutics, Inc. | 2020-09-17 | — | — | US | disclosed |
| US-20200290991-A1 | ESTER SUBSTITUTED ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. | 2020-09-17 | — | — | US | disclosed |
| US-20200290965-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. | 2020-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130380-A1 | PHOSPHONIUM ION CHANNEL BLOCKERS AND METHODS FOR USE | TRPV1, TRPV5, TRPA1 | ALDH1A1 3411/4885TDP1 3571/4885TSHR 4454/4885 |
| US-20200290953-A1 | Charged Ion Channel Blockers and Methods for Use | TRPV1, TRPV2, TRPV5 | ALDH1A1 2736/4885TDP1 4216/4885TSHR 4055/4885 |
| US-11377422-B2 | Charged ion channel blockers and methods for use | TRPV1, TRPV2, TRPV5 | ALDH1A1 2736/4885TDP1 4216/4885TSHR 4055/4885 |
| US-20210128589-A1 | PHOSPHONIUM ION CHANNEL BLOCKERS AND METHODS FOR USE | TRPV1, TRPV5, TRPA1 | ALDH1A1 3411/4885TDP1 3571/4885TSHR 4454/4885 |
| US-20210070734-A1 | ESTER SUBSTITUTED ION CHANNEL BLOCKERS AND METHODS FOR USE | TRPV1, TRPA1, TRPV2 | ALDH1A1 1138/4885TDP1 4092/4885TSHR 3755/4885 |
| US-10927096-B2 | Ester substituted ion channel blockers and methods for use | TRPV1, TRPA1, TRPV2 | ALDH1A1 1138/4885TDP1 4092/4885TSHR 3755/4885 |
| US-10842798-B1 | Charged ion channel blockers and methods for use | TRPV1, TRPV2, TRPV5 | ALDH1A1 2736/4885TDP1 4216/4885TSHR 4055/4885 |
| US-10968179-B2 | Charged ion channel blockers and methods for use | TRPV1, TRPV2, TRPV5 | ALDH1A1 2736/4885TDP1 4216/4885TSHR 4055/4885 |
| US-20210128578-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | TRPV1, TRPV2, TRPV5 | ALDH1A1 2736/4885TDP1 4216/4885TSHR 4055/4885 |
| US-20200290991-A1 | ESTER SUBSTITUTED ION CHANNEL BLOCKERS AND METHODS FOR USE | TRPV1, TRPA1, TRPV2 | ALDH1A1 1138/4885TDP1 4092/4885TSHR 3755/4885 |
| US-20200290965-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | TRPV1, TRPV2, TRPV5 | ALDH1A1 2736/4885TDP1 4216/4885TSHR 4055/4885 |
| US-11701370-B2 | Phosphonium ion channel blockers and methods for use | TRPV1, TRPV5, TRPA1 | ALDH1A1 3411/4885TDP1 3571/4885TSHR 4454/4885 |
| US-11643404-B2 | Ester substituted ion channel blockers and methods for use | TRPV1, TRPA1, TRPV2 | ALDH1A1 1138/4885TDP1 4092/4885TSHR 3755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.